IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
Overview
- Phase
- Not Applicable
- Intervention
- Interpersonal psychotherapy for major depression following perinatal loss
- Conditions
- Major Depressive Disorder
- Sponsor
- Michigan State University
- Enrollment
- 199
- Locations
- 2
- Primary Endpoint
- Time to Major Depressive Disorder recovery
- Status
- Completed
- Last Updated
- 11 days ago
Overview
Brief Summary
This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss.
Detailed Description
The goal of this study is to conduct a fully-powered randomized efficacy study of IPT for MDD following perinatal loss. Our perinatal-loss adapted group IPT will be compared to a standard depression intervention (CWD, also delivered in a group format) in a sample of 274 women experiencing MDD following perinatal loss. The proposed randomized controlled trial (RCT) will test the hypotheses that: (1) IPT for perinatal loss will result in reduced time to recovery from MDD (primary), depressive symptoms, and PTSD symptoms (secondary) relative to CWD; and that among women meeting criteria for PTSD, IPT will result in reduced time to recovery from PTSD; (2) IPT for perinatal loss will result in increased social support, social role functioning (including parental functioning for women with living children), and well-being, and decreased grief and fear of subsequent pregnancies, relative to CWD; and (3) social support and grief will mediate the effects of IPT on time to MDD recovery.
Investigators
Jennifer E. Johnson
C. S. Mott Endowed Professor of Public Health
Michigan State University
Eligibility Criteria
Inclusion Criteria
- •women who meet current Diagnostic and Statistical Manual 5 (DSM-5) criteria for major depressive disorder (MDD)
- •have experienced a perinatal loss (including early and late fetal death, death of a liveborn neonate within the first 28 days, and medically recommended termination) within the last 1-12 months
- •are 18 to 50 years old
- •speak and understand English well enough to understand questionnaires when they are read aloud
- •can provide the name and contact information of at least two locator persons
- •have access to a telephone through owning one, a relative/friend, or an agency
Exclusion Criteria
- •onset of current major depressive episode prior to news of difficulties with the pregnancy or health risk to the infant (women with prior episodes will be included)
- •current or past diagnosis of bipolar disorder, schizophrenia or other psychotic disorder
- •primary diagnosis of current substance use disorder
- •acute suicidal or homicidal risk
- •non-stable course of antidepressant medication or psychotherapy (i.e., beginning or changing dose of either within the previous 12 weeks)
- •any IPT or cognitive-behavioral treatment in the previous 12 weeks
Arms & Interventions
Interpersonal psychotherapy for major depression following perinatal loss
Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
Intervention: Interpersonal psychotherapy for major depression following perinatal loss
Coping with Depression
The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
Intervention: Coping with Depression
Outcomes
Primary Outcomes
Time to Major Depressive Disorder recovery
Time Frame: censored at 28 weeks, the proposed study duration
Assessed via the Longitudinal Interview Follow-up Evaluation (LIFE; lower is better)
Secondary Outcomes
- PTSD symptoms(8, 16, and 28 weeks after intake)
- Time to PTSD recovery(censored at 28 weeks, the proposed study duration)
- Well-being(8, 16, and 28 weeks after intake)
- Complicated grief symptoms(8, 16, and 28 weeks after intake)
- Depressive symptoms(8, 16, and 28 weeks after intake)
- Overall perceived social support(8, 16, and 28 weeks after intake)
- Dyadic social support (from partner or another important person)(8, 16, and 28 weeks after intake)
- Social role functioning (including parental functioning)(8, 16, and 28 weeks after intake)
- Grief symptoms(8, 16, and 28 weeks after intake)
- Perceived deservingness of loss and guilt over loss(8, 16, an 28 weeks after intake)
- Fear of subsequent pregnancies(8, 16, and 28 weeks after intake)